HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
13,14-dihydroprostaglandin E1
a PGE1 metabolite
Also Known As:
13,14-dihydro-PGE1; Prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,15S)-
Networked:
5
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins E: 2673
Alprostadil: 3107
13,14-dihydroprostaglandin E1: 5
Monounsaturated Fatty Acids: 676
Alprostadil: 3107
13,14-dihydroprostaglandin E1: 5
Biological Factors: 2472
Inflammation Mediators: 1113
Autacoids: 276
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins E: 2673
Alprostadil: 3107
13,14-dihydroprostaglandin E1: 5
Related Diseases
1.
Peripheral Arterial Occlusive Disease 1
01/01/1991 - "
The biosynthesis of 13,14-dihydro-PGE1 could contribute to the therapeutic efficacy of PGE1 administered intravenously in patients with peripheral arterial occlusive disease.
"
08/01/1993 - "
This view is supported by the fact that plasma levels of PGE1 and its active metabolite in patients receiving infusions of PGE1 for treatment of peripheral arterial occlusive disease are in the order of magnitude acting synergistically with neutrophil-derived NO, while direct inhibition of platelet aggregation requires considerably higher concentrations of PGE1 and 13,14-dihydro-PGE1.
"
03/01/1991 - "
Since 13,14-dihydro-PGE1, in contrast to its precursors 15-keto-PGE1 and 15-keto-13,14-dihydro-PGE1, is biologically active, its formation could contribute to the beneficial effects of PGE1 administered intravenously in patients with peripheral arterial occlusive disease.
"
01/01/1991 - "
Using high performance liquid chromatography and radioimmunoassay we have investigated the stability of prostaglandin (PG) E1 and its metabolite 13,14-dihydro-PGE1 in human plasma as well as the initial metabolism of PGE1 infused intravenously (80 micrograms/patient/hour) in patients with peripheral arterial occlusive disease.
"
09/01/1991 - "
It remains to be investigated, to which extent formation of small amounts of 13,14-dihydro-PGE1 during intravenous infusion of PGE1 could contribute to the therapeutic effects of PGE1 in patients with peripheral arterial occlusive disease.
"
2.
Congenital Heart Defects (Congenital Heart Defect)
03/01/1992 - "
Plasma concentrations of prostaglandin (PG) E1 (12-150, median 25 pg ml-1) and 13,14-dihydro-PGE1 (3-62, median 45.5 pg ml-1) were measured by gas chromatography-mass spectrometry in eight newborns with ductus arteriosus-dependent congenital heart disease during continuous intravenous infusion of PGE1.
"
Related Drugs and Biologics
1.
Alprostadil (Muse)
2.
Prostaglandins
3.
Therapeutic Uses
4.
13,14-dihydro-15-ketoprostaglandin E1
Related Therapies and Procedures
1.
Intravenous Infusions